Holen Sie sich die Stockscreener-App
2.83
1.43%
0.04
Handel nachbörslich:
2.85
0.02
+0.71%
Schlusskurs vom Vortag:
$2.79
Offen:
$2.82
24-Stunden-Volumen:
703.95K
Relative Volume:
0.63
Marktkapitalisierung:
$227.59M
Einnahmen:
$61.84M
Nettoeinkommen (Verlust:
$5.39M
KGV:
40.72
EPS:
0.0695
Netto-Cashflow:
$-11.69M
1W Leistung:
+8.02%
1M Leistung:
-4.71%
6M Leistung:
+56.35%
1J Leistung:
+30.41%
1-Tages-Spanne:
$2.78
$2.88
1-Wochen-Bereich:
$2.63
$2.98
52-Wochen-Spanne:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.83 | 224.38M | 61.84M | 5.39M | -11.69M | 0.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Finviz
Rare-disease drug maker Protalix sets 2025 financial results call for March 18 - Stock Titan
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive Investors
European Commission Approves Once-Every-Four-Weeks Elfabrio® (Pegunigalsidase Alfa) Dosing for Fabry Disease, Reducing Treatment Burden for Adults - Minichart
EC approves new Elfabrio dosing regimen - The Pharma Letter
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen - Proactive financial news
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance Indicators - Markets Mojo
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Protalix Gains EU Approval for Extended Elfabrio Dosing - TipRanks
Protalix: European Commission approves 2 mg/kg every-4-weeks dosing for Elfabrio - TradingView
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio - marketscreener.com
European Commission Approves New Dosing for Protalix (PLX) Elfab - GuruFocus
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - The Manila Times
Buybacks Report: Is Protalix BioTherapeutics Inc being accumulated by smart money2025 Year in Review & Smart Investment Allocation Insights - baoquankhu1.vn
Why hedge funds are buying Protalix BioTherapeutics Inc. stockWeekly Investment Report & Momentum Based Trading Signals - Naître et grandir
Buybacks Report: Will Protalix BioTherapeutics Inc benefit from government policyJuly 2025 Big Picture & Short-Term High Return Strategies - baoquankhu1.vn
Retail Trends: Should I invest in Protalix BioTherapeutics Inc before earningsJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
MAK Capital Group (PLX) reports 4,649,599 shares, a 5.8% stake - Stock Titan
Published on: 2026-03-01 19:16:31 - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Protalix BioTherapeutics Reports First Quarter 2025 Financial an - GuruFocus
PLX Should I Buy - Intellectia AI
Protalix BioTherapeutics (NYSE:PLX) Shares Down 0.7%Time to Sell? - MarketBeat
Protalix Biotherapeutics Hits New 52-Week High of $3.19 - Markets Mojo
Is Protalix BioTherapeutics Inc a top pick in the sectorTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Published on: 2026-02-21 10:08:13 - baoquankhu1.vn
What is the PEG ratio of Protalix BioTherapeutics Inc.Earnings Trend Report & Safe Entry Trade Signal Reports - mfd.ru
Should I invest in Protalix BioTherapeutics Inc. before earnings2025 AllTime Highs & Risk Controlled Stock Pick Alerts - mfd.ru
Swing Trade: Will Protalix BioTherapeutics Inc benefit from rising consumer demandMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why Protalix BioTherapeutics Inc. stock could be next big winnerEarnings Summary Report & Safe Entry Momentum Stock Tips - mfd.ru
Shorts Report: Will Protalix BioTherapeutics Inc. (DE) stock outperform benchmarks2025 Macro Impact & Daily Risk Controlled Trade Plans - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from rising consumer demandGap Down & Short-Term Trading Alerts - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from government policy2025 Price Momentum & Weekly Momentum Stock Picks - mfd.ru
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing - TipRanks
Protalix BioTherapeutics, Inc. Announces Positive CHMP Opinion for Elfabrio® - TradingView
Why retail investors favor Protalix BioTherapeutics Inc. stockTrade Analysis Report & Risk Adjusted Swing Trade Ideas - mfd.ru
Fabry Disease Market Hits USD 1.7 Billion in 2024, Set for Strong Expansion Across the 7MM Through 2034 | DelveInsight - Barchart.com
RSI Check: Is Protalix BioTherapeutics Inc currently under institutional pressureWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Aug Patterns: Should I invest in Protalix BioTherapeutics Inc before earnings2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Protalix Biotherapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - Defense World
Protalix BioTherapeutics (NYSE:PLX) Trading Up 6.2%Here's Why - MarketBeat
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT) - Defense World
Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22 - Nasdaq
PLX: CHMP Delivers Positive Opinion - Research Tree
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
Protalix's New Dosing Regimen Recommended for Approval - Intellectia AI
Protalix (PLX) Surges 14% on Positive EMA Panel Opinion for Elfa - GuruFocus
Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha
Protalix (PLX) Gains Positive EMA Opinion for New Elfabrio Dosage - GuruFocus
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):